Immuron reveals anti-Covid potential, raises $28 million

Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors. On Tuesday the company reported its Travelan product for the prevention of travellers’ diarrhoea demonstrated neutralising activity against severe acute respiratory syndrome coronovirus-2, the virus that causes…

Cabinet makers link up with Australian Made

The Australian Made Campaign (AMCL) has welcomed the Australian Cabinet and Furniture Association (ACFA) as an associate to support the continued growth of Australia’s local furnishings and furniture manufacturing sector. NSW-based ACFA is one of Australia’s primary industry associations for furnishing, cabinetmaking and joinery manufacturers, along with the semi-national Australasian Furnishing Association, which is also…

Bluglass installs commercial-scale semiconductor equipment at Silverwater plant

Semiconductor technology developer Bluglass has completed the installation of its largest-ever remote plasma vapour deposition (RPCVD) manufacturing system (main picture) at its Silverwater plant in Sydney. The commercial-scale system, known as BLG-500, is capable of creating 6×6 semiconductor wafers or 42 two inch wafers for the production of laser diodes, LED and microLED industries. It…

BlueScope results reflect Covid impact

BlueScope Steel has revealed a strong result for the 2020 financial year with its results in the 18 countries where it operates reflecting local fallout from the Covid-19 pandemic. Business was disrupted by compulsory industry closures in some markets such as Malaysia and the United States, China is recovering strongly and the company is reviewing…

Monday news briefs – stories you might have missed

Respiri secures global sales and distribution agreement Asthma management system developer Respiri has signed an exclusive agreement with pharmaceutical firm Cipla to sell its Wheezo asthma management device. Cipla will initially market Wheezo in Australia and New Zealand, with further territories including the United States, Europe and India also on Cipla’s radar. Initial minimum sales…